BiotechTube
Home/Pipeline/Function-based Consortium for IBD

Function-based Consortium for IBD

Inflammatory Bowel Disease

Pre-clinicalActive

Key Facts

Indication
Inflammatory Bowel Disease
Phase
Pre-clinical
Status
Active
Company
PharmaBiome

About PharmaBiome

PharmaBiome is a pre-clinical stage biotech pioneering a function-based approach to microbiome therapeutics. Originating from ETH Zurich, its platform focuses on engineering consortia of bacteria based on their metabolic interactions to restore core functions lost in dysbiosis. The company has established key R&D collaborations with industry partners like Ferring and Roquette and is advancing its science towards targeted therapies for inflammatory and other microbiome-linked conditions.

View full company profile

Therapeutic Areas

Inflammatory Bowel DiseaseGastrointestinal Disorders

Other Inflammatory Bowel Disease Drugs

DrugCompanyPhase
DVI-001DivamicsPreclinical
DVI-002DivamicsPreclinical
Turq-101Turquoise BiotechnologiesPreclinical
GS-4875GileadPhase 2
Galapagos CollaborationScipher MedicineDiscovery/Pre-clinical
IBD SubclassificationBio-MeResearch
Anti-iRhom2 antibodiesSciRhomPre-clinical
IBD Multi-omics DatasetOvation.ioCommercial
Noa‑001Noa TherapeuticsPreclinical
InflectraEMSPhase 3
IW-601ImmuneWalk TherapeuticsPreclinical
TRWR‑IBDTaiwan Resonant Waves ResearchPreclinical